Press Releases Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Delayed Japan Exchange Other stock markets 09:14:38 2024-07-16 pm EDT			5-day change	1st Jan Change
3,480 ^JPY	-0.26%		+0.75%	-30.38%

Apr. 10	Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy	MT
Mar. 18	Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nippon Shinyaku : Notice Of Resolutions Of The 161st Annual General Meeting of Shareholders PDF141 KB	Jun. 27	PU
Nippon Shinyaku : Japan’s PMDA approves Antineoplastic Agent "Jaypirca® 50 mg and 100 mg tablets" for Patients with Relapsed or Refractory MCL Who are Resistant or Intolerant to Other BTK Inhibitors	Jun. 24	PU
Nippon Shinyaku : Notice of The 161st Annual General Meeting of Shareholder	Jun. 03	PU
Nippon Shinyaku : The 7th Five Year Medium Term Management Plan "For Global Growth Beyond the Cliff”	May. 27	PU
Nippon Shinyaku : Viltolarsen (NS 065/NCNP 01) for the treatment of Duchenne Muscular Dystrophy Preliminary Results of the Analysis of the Phase III Trial (RACER53 Study)	May. 27	PU
Nippon Shinyaku : Notice Regarding Introduction of a Restricted Stock Compensation Plan	May. 24	PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (Script+Q&A(Summary))P	May. 22	PU
Nippon Shinyaku : Launch of VyxeosⓇ Combination for I.V. Injection for the Treatment of High-risk AML in Japan	May. 21	PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (Script)P	May. 17	PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR MeetingP	May. 14	PU
Nippon Shinyaku : Outline of Consolidated Financial Results for the Year Ended March 31, 2024	May. 10	PU
Interim report January-March 2024	May. 03	AQ
Nippon Shinyaku : Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW	Apr. 16	PU
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases	Apr. 05	AQ
Nippon Shinyaku : Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System	Apr. 04	PU
Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan	Mar. 26	PU
Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan	Mar. 26	PU
Nippon Shinyaku : Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan	Mar. 25	PU
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Mar. 06	PU
Year-end report 2023	Feb. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Press Releases

Filters